Loading
Nanjing Immunophage Biotech is a Chinese developer in Nanjing that sponsors 2 registered cancer trials of IPG1094 and IPG7236.
Nanjing Immunophage Biotech appears on ClinicalTrials.gov as the industry sponsor of 2 interventional cancer trials (phase 1/2), testing IPG1094, IPG7236, Toripalimab in solid tumor, advanced solid tumor. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.
IPG1094 is a small-molecule inhibitor from Nanjing Immunophage Biotech Co., Ltd, in registered phase 2 trials for metastatic cancer.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.